SCIO Scios Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc.

SCIO 0.01000

0.0%

Aug 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1459)	2/7/2003 6:36:49 PM
From: Ausdauer	Read Replies (2) of 1477

Peter, no, I mean that the marketing has been fierce... ...not that you overexagerated drug efficacy. I see Natrecor as an interesting therapy, but not a blockbuster. Here is another big secret... NOBODY USES IV NITRO FOR ACUTE CHF DECOMPENSATIONS. JNJ's interest, IMHO, is something other than Natrecor, with Nesiritide being a cherry on top of the pie. I am not sure what the pie is. "Experts" in the industry tell me that Natrecor was priced incorrectly. They sell it too cheaply. Sure, that could change if volume sales increase with OP infusions, but I see that as a long way away. You either need a dedicated clinic or a portable infusion system. Oh, yes, and a clinical trial that would justify its use. JNJ is looking for an oral equivalent of Remicaide. I suspect that is the hook here. Start thinking of some cute names now. How about Rambocaide? Aus

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next